Abstract： According to the medical history, imaging and pathological diagnosis, the advanced gastric cancer patients able to tolerate radiotherapy can be divided into the following three groups:(1) unresectable locally advanced or locally recurrent disease;(2) metastatic disease at primary diagnosis with stage Ⅳ;(3) patients experiencing severe tumor-related clinical symptoms. The role of palliative radiotherapy in patients with advanced gastric cancer would be discussed by reviewing 33 articles (8 in last five years, 13 in ten years).
Wang Xin,Jin Jing. Research progress in palliative radiotherapy for advanced gastric cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(1): 85-89.
[1]Al-Batran SE,Hartmann JT,Probst S,et al. Phase Ⅲ trial in metastatic gastroesophageal adenocarcinoma with fluorouracil,leucovorin plus either oxaliplatin or cisplatin:a study of the Arbeitsgemeinschaft Internistische Onkologie[J].J Clin Oncol,2008,26(9):1435-1442.DOI:10.1200/JCO.2007.13.9378. [2]Van Cutsem E,Moiseyenko VM,Tjulandin S,et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991-4997.DOI:10.1200/JCO.2006.06.8429. [3]Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.DOI:10.1016/S1470-2045(08)70035-4. [4]Ajani JA,Rodriguez W,Bodoky G,et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28(9):1547-1553.DOI:10.1200/JCO.2009.25.4706. [5]Moertel CG,Childs DS,Reitemeier RJ,et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer[J].Lancet,1969,294(7626):865-867.DOI:10.1016/S0140-6736(69)92326-5. [6]Henning GT,Schild SE,Stafford SL,et al. Results of irradiation or chemoirradiation for primary unresectable,locally recurrent,or grossly incomplete resection of gastric adenocarcinomas[J].Int J Radiat Oncol Biol Phys,2000,46(1):109-118.DOI:10.1016/S0360-3016(99)00379-X. [7]Shchepotin IB,Evans SRT,Chorny V,et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma[J].Surg Oncol,1994,3(1):37-44.DOI:10.1016/0960-7404(94)90022-1. [8]Bleiberg H,Goffin JC,Dalesio O,et al. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC[J].Eur J Surg Oncol,1989,15(6):535-543. [9]Gérard JP,Conroy T,Bonnetain F,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:results of FFCD 9203[J].J Clin Oncol,2006,24(28):4620-4625.DOI:10.1200/JCO.2006.06.7629. [10]Bosset JF,Calais G,Mineur L,et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer:preliminary results-EORTC 22921[J].J Clin Oncol,2005,23(24):5620-5627.DOI:10.1200/JCO.2005.02.113. [11]Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group[J].JAMA,1999,281(17):1623-1627.DOI:10.1001/jama.281.17.1623. [12]Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J].J Clin Oncol,2001,19(2):305-313. [13]Gastrointestinal Tumor Study Group. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma[J].Cancer,1982,49(9):1771-1777.DOI:10.1002/1097-0142(19820501)49:9<1771::AID-CNCR2820490907>3.0.CO;2-M. [14]Saikawa Y,Kubota T,Kumagai K,et al. Phase Ⅱ study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer[J].Int J Radiat Oncol Biol Phys,2008,71(1):173-179.DOI:10.1016/j.ijrobp.2007.09.010. [15]Fujitani K,Tsujinaka T,Yamasaki H,et al. Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy[J].Anticancer Res,2009,29(8):3385-3391. [16]Safran H,Wanebo HJ,Hesketh PJ,et al. Paclitaxel and concurrent radiation for gastric cancer[J].Int J Radiat Oncol Biol Phys,2000,46(4):889-894.DOI:10.1016/S0360-3016(99)00436-8. [17]Bang YJ,Van Cutsem E,Feyereislova A,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.DOI:10.1016/S0140-6736(10)61121-X. [18]Lu N,Jin J,Li Y,et al. Prospective phase 2 trial of Nimotuzumab and concurrent capecitabine and radiotherapy for patients with locally advanced inoperable or relapsed/residual gastric cancer:final analysis[J].Int J Radiat Oncol Biol Phys,90(1):S353.DOI:10.1016/j.ijrobp.2014.05.1148. [19]Gunderson LL,Hoskins RB,Cohen AC,et al. Combined modality treatment of gastric cancer[J].Int J Radiat Oncol Biol Phys,1983,9(7):965-975.DOI:10.1016/0360-3016(83)90383-8. [20]Kim MM,Rana V,Janjan NA,et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer[J].Acta Oncol,2008,47(3):421-427.DOI:10.1080/02841860701621233. [21]Suzuki A,Xiao L,Taketa T,et al. Localized gastric cancer treated with chemoradation without surgery:UTMD anderson cancer center experience[J].Oncology,2012,82(6):347-351.DOI:10.1159/000338318. [22]Yuan ST,Wang FL,Liu N,et al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence[J].Am J Clin Oncol,2015,38(2):130-134.DOI:10.1097/COC.0b013e31828f5cb6. [23]Meijer S,De Bakker OJCB,Hoitsma HFW.Palliative resection in gastric cancer[J].J Surg Oncol,1983,23(2):77-80.DOI:10.1002/jso.2930230205. [24]Sun J,Sun YH,Zeng ZC,et al. Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer[J].Int J Radiat Oncol Biol Phys,2010,77(2):384-391.DOI:10.1016/j.ijrobp.2009.05.019. [25]Kim BH,Eom KY,Kim JS,et al. Role of salvage radiotherapy for regional lymph node recurrence after radical surgery in advanced gastric cancer[J].Radiat Oncol J,2013,31(3):147-154.DOI:10.3857/roj.2013.31.3.147. [26]Yoshida K,Yamaguchi K,Okumura N,et al. The roles of surgical oncologists in the new era:minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer[J].Pathobiology,2011,78(6):343-352.DOI:10.1159/000328197. [27]Shridhar R,Almhanna K,Hoffe SE,et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer:a Surveillance,Epidemiology,and End Results database analysis[J].Cancer,2013,119(9):1636-1642.DOI:10.1002/cncr.27927. [28]Tey J,Back MF,Shakespeare TP,et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer[J].Int J Radiat Oncol Biol Phys,2007,67(2):385-388.DOI:10.1016/j.ijrobp.2006.08.070. [29]Hashimoto K,Mayahara H,Takashima A,et al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer:a single institute experience[J].J Cancer Res Clin Oncol,2009,135(8):1117-1123.DOI:10.1007/s00432-009-0553-0. [30]Asakura H,Hashimoto T,Harada H,et al. Palliative radiotherapy for bleeding from advanced gastric cancer:is a schedule of 30 Gy in 10 fractions adequate?[J].J Cancer Res Clin Oncol,2011,137(1):125-130.DOI:10.1007/s00432-010-0866-z. [31]Lee JA,Lim do H,Park W,et al. Radiation therapy for gastric cancer bleeding[J].Tumori,2009,95(6):726-730. [32]Mantell BS.Radiotherapy for dysphagia due to gastric carcinoma[J].Br J Surg,1982,69(2):69-70.DOI:10.1002/bjs.1800690203. [33]Coia LR,Paul AR,Engstrom PF.Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction[J].Cancer,1988,61(4):643-649.DOI:10.1002/1097-0142(19880215)61:4<643::AID-CNCR2820610404>3.0.CO;2-4.
2016, Vol. 25 
